Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. 2016

Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko

Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein-induced neuropathology. In mice expressing a human α-synucleinopathy-associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein-induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.

UI MeSH Term Description Entries
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000066829 Neuroprotection The physiological processes and techniques used by the body to prevent neuronal injury and degeneration in the central nervous system following acute disorders or as a result of chronic neurodegenerative diseases. Neural Protection,Neuron Protection,Neuronal Protection,Protection, Neural,Protection, Neuron,Protection, Neuronal

Related Publications

Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
April 1998, Journal of immunology (Baltimore, Md. : 1950),
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
June 2000, Oncogene,
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
April 1998, Oncogene,
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
February 2012, The Journal of biological chemistry,
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
November 2023, Trends in molecular medicine,
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
June 2000, The Journal of biological chemistry,
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
July 2000, Molecular and cellular biology,
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
January 2006, Stem cells (Dayton, Ohio),
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
October 2005, The oncologist,
Saurav Brahmachari, and Preston Ge, and Su Hyun Lee, and Donghoon Kim, and Senthilkumar S Karuppagounder, and Manoj Kumar, and Xiaobo Mao, and Joo Ho Shin, and Yunjong Lee, and Olga Pletnikova, and Juan C Troncoso, and Valina L Dawson, and Ted M Dawson, and Han Seok Ko
January 1989, The Italian journal of biochemistry,
Copied contents to your clipboard!